Accenture has made a strategic investment, through Accenture Ventures, in Ocean Genomics, a technology and AI company that has developed advanced computational platforms to assist biopharma companies to discover and develop more effective diagnostics and therapeutics.
Based in Pittsburgh, U.S., Ocean Genomics creates software that provides modeling and an understanding of changes and variants in mRNA to enable a more accurate prediction of a patient’s biological response to a drug.
Petra Jantzer, Ph.D., a senior managing director and global lead of Accenture’s Life Sciences practice, said, “The growth of in-silico in the discovery of individualized treatments and disease interventions will change how we care for people around the world. We made this strategic investment in Ocean Genomics to help biopharma companies better utilize genomic and transcriptomic data and AI in drug discovery to develop targeted therapeutics at a higher pace and bring them to market faster.”
Scientific and technological advancements are creating breakthroughs for patient health, resulting in more complex and personalized therapies. This New Science, a dynamic combination of the best in science and health technology, is expected to drive 81 percent of biopharma revenue growth.
“As biopharma companies move to increasingly precise and effective therapies, they seek the talent, technology and insights to enable more personalized, data-driven drug discovery,” said Carl Kingsford, Ph.D., co-founder and CEO of Ocean Genomics. “With the support of, and collaboration with, Accenture, we will be even better positioned to help the biopharma industry develop more effective diagnostics and therapeutics.”
Ocean Genomics is now a part of Accenture Ventures’ Project Spotlight, an engagement and investment program that connects emerging technology startups with the Global 2000 to fill strategic innovation gaps. Project Spotlight offers extensive access to Accenture’s domain expertise and its enterprise clients, helping startups harness human creativity and deliver on the promise of their technology.
“Ocean Genomics’ technology platform integrates gene expression, molecular features, clinical and genomics data and advanced AI algorithms to better understand and predict the biological impact of diseases and therapies,” said Tom Lounibos, managing director, Accenture Ventures. “With Ocean Genomics now part of Project Spotlight, we will look to collaborate with our clients in the Life Sciences industry and beyond on new ways to combine RNA, AI and other emerging technologies to advance drug development, personalized medicine, and human health.”
Terms of the transaction were not disclosed.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.